


Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2019  
Document Type: USP Monographs  
DocId: GUID-BDC7D5E6-856E-4B9E-9C33-FCF20D01E040\_6\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M40520\\_06\\_01](https://doi.org/10.31003/USPNF_M40520_06_01)  
DOI Ref: 0hdf0

© 2025 USPC  
Do not distribute

# Insulin

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click <https://www.uspnf.com/rb-insulin-20190401>

Change to read:



C<sub>256</sub>H<sub>381</sub>N<sub>65</sub>O<sub>76</sub>S<sub>6</sub> 5777.54  
Insulin (pig) CAS RN®: 12584-58-6.

▲▲ (RB 1-May-2019)

## DEFINITION

Change to read:

▲Insulin is a two-chain peptide hormone consisting of 51 amino acids, and its structure corresponds to native insulin produced in vivo by the beta cells of the pancreas. The A-chain is composed of 21 amino acids, and the B-chain is composed of 30 amino acids.▲ (USP 1-May-2019) It is obtained from the pancreas of healthy ▲▲ (RB 1-May-2019) porcine animals, ▲▲ (RB 1-May-2019) used for food by humans. Its potency is NLT 26.5 USP Insulin Units/mg, calculated on the dried basis; Insulin labeled as purified contains NLT 27.0 USP Insulin Units/mg, calculated on the dried basis. ▲▲ (USP 1-May-2019)

[NOTE—1 USP Insulin Unit is equivalent to ▲▲ (RB 1-May-2019) 0.0345 mg of pure Insulin derived from pork.]

## IDENTIFICATION

Change to read:

- **A.** The retention time of the major peak in the *Sample solution* corresponds to that ▲▲ (RB 1-May-2019) of the *Identification solution*, as obtained in the Assay▲ and no other significant peaks are observed.▲ (RB 1-May-2019)

[NOTE—It may be necessary to inject a mixture of *Sample solution* and *Identification solution*.]

Delete the following:

### ▲B. PEPTIDE MAPPING

- Sulfate buffer:** 2.0 M ammonium sulfate and 0.5 M sulfuric acid (1:1)
- Enzyme solution:** 500 units/mL of *Staphylococcus aureus* V-8 protease activity in water
- HEPES buffer:** 0.1 M HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid). Adjust with 5 M sodium hydroxide to a pH of 7.5 before diluting with water to a final volume.
- Solution A:** Acetonitrile, water, and *Sulfate buffer* (100:700:200)
- Solution B:** Acetonitrile, water, and *Sulfate buffer* (400:400:200)
- Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10

Time (min)	Solution A (%)	Solution B (%)
60	30	70
65	0	100
70	0	100
71	90	10
86	90	10

**Standard digest solution:** 2 mg/mL of [USP Insulin RS](#) of the appropriate species in 0.01 N hydrochloric acid. Transfer 500 µL of the resulting solution to a clean vial. Add 2.0 mL of *HEPES buffer* and 400 µL of *Enzyme solution*, and incubate at 25° for 6 h. Quench the digestion by adding 2.9 mL of *Sulfate buffer*.

**Sample digest solution:** 2 mg/mL of Insulin in 0.01 N hydrochloric acid, mix to dissolve. Transfer 500 µL of the resulting solution to a clean vial. Add 2.0 mL of *HEPES buffer* and 400 µL of *Enzyme solution*, and incubate at 25° for 6 h. Quench the digestion by adding 2.9 mL of *Sulfate buffer*.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 214 nm

**Column:** 4.6-mm × 10-cm; packing L1

**Column temperature:** 40°

**Flow rate:** 1 mL/min

#### System suitability

**Sample:** *Standard digest solution*

#### Suitability requirements

**Chromatogram comparability:** The chromatogram of the *Standard digest solution* corresponds to that of the reference chromatogram provided with [USP Insulin RS](#) of the appropriate species.

**Resolution:** NLT 1.9 between digest fragments II and III.

[NOTE—Fragment I elutes at the same time in insulin derived from pork and Insulin Human; Fragment II elutes at the same time in Insulin Human and insulin derived from beef and pork; and Fragment III elutes at the same time in insulin derived from beef and pork.]

**Tailing factor:** NMT 1.5

#### Analysis

**Samples:** *Standard digest solution* and *Sample digest solution*

Using the gradient program, run a blank. Separately inject equal volumes of the *Standard digest solution* and the *Sample digest solution*, and record the responses of each peak.

**Acceptance criteria:** The chromatographic profile of the *Sample digest solution* corresponds to that of the *Standard digest solution*. ▲ (USP 1-May-2019)

#### Add the following:

▲ • **B. [PHYSICOCHEMICAL ANALYTICAL PROCEDURES FOR INSULINS \(121.1\), Peptide Mapping](#):** Proceed as directed in the chapter, except for the *Mobile phase* and *System suitability*.

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	90	10
60	30	70
65	0	100

Time (min)	Solution A (%)	Solution B (%)
70	0	100
71	90	10
86	90	10

**System suitability****Sample:** *Standard solution***Suitability requirements****Resolution:** NLT 1.9 between digest fragments II and III

[NOTE—Fragment I elutes at the same time in insulin derived from pork and Insulin Human; Fragment II elutes at the same time in Insulin Human and insulin derived from beef and pork; and Fragment III elutes at the same time in insulin derived from beef and pork.]

**Tailing factor:** NMT 1.5 for digest fragments II and III**Chromatogram similarity:** The chromatogram of the *Standard solution* corresponds to that of the reference chromatogram provided with [USP Insulin Pork RS](#).**Acceptance criteria:** Meets the requirements▲ (USP 1-May-2019)**Add the following:**▲ • C. [INSULIN ASSAYS \(121\)](#), [Assay](#), [Bioidentity Test](#): Meets the requirements▲ (USP 1-May-2019)**ASSAY****Change to read:**• **PROCEDURE****Solution A:** Dissolve 28.4 g of [anhydrous sodium sulfate](#) in 1000 mL of [water](#). Pipet 2.7 mL of [phosphoric acid](#) into the solution, and adjust with [ethanolamine](#) to a pH of 2.3, if necessary.**Mobile phase:** Acetonitrile and *Solution A* (26:74). [NOTE—The acetonitrile is warmed to a temperature of NLT 20° to avoid precipitation.]**System suitability solution:** 1.5 mg/mL of Insulin in [0.01 N hydrochloric acid](#). Allow to stand at room temperature for NLT 3 days to obtain a solution containing NLT 5% of A-21 desamido insulin.[NOTE—The *Identification solution*, *Standard solution*, and *Sample solution* may be stored at room temperature for up to 12 h or in a refrigerator for up to 48 h.]**Identification solution:** 0.6 mg/mL of [USP Insulin Pork RS](#)▲ (RB 1-May-2019) in [0.01 N hydrochloric acid](#)**Standard solution:** 1.5 mg/mL of ▲[USP Insulin Pork RS](#)▲ (RB 1-May-2019) in [0.01 N hydrochloric acid](#)▲ (RB 1-May-2019)**Sample solution:** 1.5 mg/mL of Insulin in [0.01 N hydrochloric acid](#)**Chromatographic system**(See [Chromatography \(621\)](#), [System Suitability](#).)**Mode:** LC**Detector:** UV 214 nm**Column:** 4.6-mm × 15-cm; packing [L1](#)**Column temperature:** 40°**Flow rate:** 1 mL/min**Injection volume:** 20 µL**System suitability****Samples:** *System suitability solution* and *Standard solution***Suitability requirements****Resolution:** NLT 2.0 between insulin and A-21 desamido insulin, *System suitability solution***Tailing factor:** NMT 1.8 for the insulin peak, *System suitability solution***Relative standard deviation:** NMT 1.6%, *Standard solution***Analysis****Samples:** *Identification solution*, *Standard solution*, and *Sample solution*Measure the peak responses for insulin and A-21 desamido insulin, using the chromatogram of the *Identification solution* to identify the insulin peaks.▲ (RB 1-May-2019) Calculate the potency on the undried basis, in USP Insulin Units/mg, of Insulin in the *Sample solution*:

$$\text{Result} = (\Sigma r_U / \Sigma r_S) \times (C_S / C_U)$$

$r_U$  = sum of the peak responses of insulin and A-21 desamido insulin from the *Sample solution*

$r_S$  = sum of the peak responses of insulin and A-21 desamido insulin from the *Standard solution*

$C_S$  = concentration of ▲ (RB 1-May-2019) [USP Insulin Pork RS](#) in the *Standard solution* (USP Insulin Units/mL)

$C_U$  = concentration of Insulin in the *Sample solution* (mg/mL)

▲ (RB 1-May-2019)

**Acceptance criteria:** NLT 26.5 USP Insulin Units/mg on the dried basis; Insulin labeled as purified contains NLT 27.0 USP Insulin Units/mg on the dried basis.

## OTHER COMPONENTS

**Change to read:**

- [ZINC DETERMINATION \(591\)](#).

▲ **Acceptance criteria:** NMT 1.0% on the dried basis ▲ (USP 1-May-2019)

## PRODUCT-RELATED SUBSTANCES AND IMPURITIES

**Change to read:**

- ▲ **PRODUCT-RELATED SUBSTANCES** ▲ (USP 1-MAY-2019)

**Solution A:** Dissolve 28.4 g of [anhydrous sodium sulfate](#) in 1000 mL of [water](#). Pipet 2.7 mL of [phosphoric acid](#) into the solution, and adjust with [ethanolamine](#) to a pH of 2.3, if necessary.

**Solution B:** Acetonitrile and *Solution A* (18:82)

**Solution C:** Acetonitrile and *Solution A* (50:50)

**Mobile phase:** See [Table 2](#).

**Table 2**

Time (min)	Solution B (%)	Solution C (%)
0	81	19
60	81	19
85	36	64
91	36	64
92	81	19

**System suitability solution:** 1.5 mg/mL of Insulin in [0.01 N hydrochloric acid](#). Allow to stand at room temperature for NLT 3 days to obtain a solution containing NLT 5% of A-21 desamido insulin.

[NOTE—*Standard solutions A–C* may be stored at room temperature for up to 12 h and in a refrigerator for up to 48 h.]

**Standard solution A:** 3.75 mg/mL of ▲ [USP Insulin Pork RS](#) ▲ (RB 1-May-2019) in [0.01 N hydrochloric acid](#) ▲ (RB 1-May-2019)

**Standard solution B:** 0.375 mg/mL of ▲ (RB 1-May-2019) [USP Insulin Pork RS](#) in [0.01 N hydrochloric acid](#) prepared as follows. Pipet 1 mL of *Standard solution A* into a 10-mL volumetric flask, dilute with [0.01 N hydrochloric acid](#) to volume, and mix.

**Standard solution C:** 0.0375 mg/mL of ▲ (RB 1-May-2019) [USP Insulin Pork RS](#) in [0.01 N hydrochloric acid](#) prepared as follows. Pipet 1 mL of *Standard solution B* into a 10-mL volumetric flask, dilute with [0.01 N hydrochloric acid](#) to volume, and mix.

**Sample solution:** 3.75 mg/mL of Insulin in [0.01 N hydrochloric acid](#). Prepare the solution in a capped vial, cap the vial, and shake gently to dissolve. Store the solution for NMT 2 h at room temperature or for NMT 12 h in a refrigerator.

## Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 214 nm

**Column:** 4.6-mm × 25-cm; packing [L1](#)

**Column temperature:** 40°

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *System suitability solution, Standard solution A, Standard solution B, and Standard solution C*

[NOTE—Adjust the *Mobile phase* composition and the duration of the isocratic elution to obtain a retention time of about 31 min for insulin, with the A-21 desamido insulin eluting just prior to the start of the gradient elution phase.]

#### Suitability requirements for the System suitability solution

**Resolution:** NLT 2.0 between insulin and A-21 desamido insulin

**Tailing factor:** NMT 1.8 for the insulin peak

#### Suitability requirements for the Standard solutions

Calculate the factor  $X_1$ :

$$X_1 = (r_B/r_A) \times D$$

$r_B$  = peak response from *Standard solution B*

$r_A$  = peak response from *Standard solution A*

$D$  = dilution factor, 10

**Result:** Between 0.91 and 1.09

Calculate the factor  $X_2$ :

$$X_2 = (r_C/r_A) \times D$$

$r_C$  = peak response from *Standard solution C*

$r_A$  = peak response from *Standard solution A*

$D$  = dilution factor, 100

**Result:** Between 0.7 and 1.3

#### Analysis

**Sample:** *Sample solution*

Calculate the percentage of insulin, A-21 desamido insulin, and other ▲insulin-related substances▲ (USP 1-May-2019) in the portion of

Insulin taken:

Calculate the percentage of Insulin (%):

$$\text{Result} = (r_I/r_T) \times 100$$

$r_I$  = peak response of insulin from the *Sample solution*

$r_T$  = sum of the responses of all the peaks from the *Sample solution*

Calculate the percentage of A-21 desamido insulin (%D):

$$\text{Result} = (r_D/r_T) \times 100$$

$r_D$  = peak response of A-21 desamido insulin from the *Sample solution*

$r_T$  = sum of the responses of all the peaks from the *Sample solution*

Calculate the percentage of other insulin-related ▲substances:▲ (USP 1-May-2019)

$$\text{Result} = 100 - (\%I + \%D)$$

**Acceptance criteria:** NMT 10.0% of A-21 desamido insulin, and NMT 5.0% of other insulin-related ▲substances▲ (USP 1-May-2019)

▲ (RB 1-May-2019)

**Change to read:**

- ▲ [PHYSICOCHEMICAL ANALYTICAL PROCEDURES FOR INSULINS \(121.1\)](#), [Limit of High Molecular Weight Proteins](#): Meets the requirements ▲ (USP 1-May-2019)

**Acceptance criteria:** NMT 1.0%

**PROCESS-RELATED IMPURITIES****Add the following:**

- ▲ **PROINSULIN CONTENT:** NMT 10 ng/mg, determined by a validated method ▲ (USP 1-May-2019)

**SPECIFIC TESTS****Delete the following:**

- ▲ [INSULIN ASSAYS \(121\)](#), [Assay, Bioidentity Test](#): Meets the requirements ▲ (USP 1-May-2019)

- [LOSS ON DRYING \(731\)](#)

**Sample:** 200 mg

**Analysis:** Dry the *Sample* at 105° for 16 h.

**Acceptance criteria:** NMT 10.0%

**Delete the following:**

- ▲ [ZINC DETERMINATION \(591\)](#), [Procedure, Dithizone Method](#)

**Sample:** 10 mg

**Acceptance criteria:** NMT 1.0% on the dried basis ▲ (USP 1-May-2019)

- [BACTERIAL ENDOTOXINS TEST \(85\)](#): NMT 10 USP Endotoxin Units/mg of insulin

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total bacterial count does not exceed  $3 \times 10^2$  cfu/g, the test being performed on a portion of about 0.2 g, accurately weighed.

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store, protected from light, in a freezer.

**Change to read:**

- **LABELING:** Label it ▲ (RB 1-May-2019) as pork ▲ (RB 1-May-2019). If the Insulin is purified, label it as such.

**Change to read:**

- [USP REFERENCE STANDARDS \(11\)](#)

▲ (RB 1-May-2019)

[USP Insulin Pork RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
INSULIN	<a href="#">Jennifer Tong Sun</a> Senior Scientist II	BI02 Biologics Monographs 2 - Proteins

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(4)

**Current DocID:** GUID-BDC7D5E6-856E-4B9E-9C33-FCF20D01E040\_6\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M40520\\_06\\_01](https://doi.org/10.31003/USPNF_M40520_06_01)

**DOI ref:** [0hdf0](#)